Loading
Alaunos Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Dec 2022.
Alaunos Therapeutics, Inc.: what insiders have been doing
Alaunos Therapeutics, Inc., founded in 2005, is a Health Care company based in Boston, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 21 filings were filed, from 4 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Insider buying of Alaunos Therapeutics, Inc. has been absent for the past year. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
With 21 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 8 purchases and 3 sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Boston, United States · Founded: 2005
Source: Wikidata (CC0).
Insider Decl.
70
Thresholds
n/a
Buy Volume
€2M
8 ops. · all time
Sell Volume
€35,665
3 ops. · all time
Who traded when
BuySaleJaime Vieser1 sale
Since the insiders bought
- -89.7%Entry US$102.00 · Close at T+365 US$10.50
- -89.7%Entry US$102.00 · Close at T+365 US$10.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.18
Analyst consensus
Income statement
RevenueUS$5k
EBITDA-US$4.2M-84360% margin
Net income-US$4.2M-83520.0% margin
Valuation
P/Book8.3x
Beta-0.87
Balance sheet & cash
Market capUS$6.4M
Free Cash Flow-US$3M
Profitability & ownership
ROE-185.9%
ROA-81.1%
% insiders16.3%
% institutions4.2%
Last declaration on 8 October 2026
Declarations70 total
23,564 shares@ US$0.74440.75% mcap40.6% of flowCommon StockSEC:0001193125-26-417970:0
22,669 shares@ US$0.74440.72% mcap1.7% of flowCommon StockSEC:0001193125-26-417971:0
21,829 shares@ US$0.74440.70% mcap2.4% of flowCommon StockSEC:0001193125-26-417969:0
20,990 shares@ US$0.74440.67% mcap21.1% of flowCommon StockSEC:0001193125-26-417974:0
4,363 shares@ US$2.010.31% mcap33.3% of flowCommon StockSEC:0001193125-26-344682:0
8,789 shares@ US$1.920.61% mcap1.7% of flowCommon StockSEC:0001193125-26-318100:0
8,463 shares@ US$1.920.58% mcap2.4% of flowCommon StockSEC:0001193125-26-318103:0
4,568 shares@ US$1.920.32% mcap33.7% of flowCommon StockSEC:0001193125-26-318105:0
8,138 shares@ US$1.920.56% mcap26.3% of flowCommon StockSEC:0001193125-26-318114:0
3,880 sharesCommon StockSEC:0001193125-26-295004:0
7,761 sharesCommon StockSEC:0001193125-26-274305:0
3,700 shares@ US$2.370.19% mcap33.1% of flowCommon StockSEC:0001193125-26-241999:0
6,274 shares@ US$2.590.31% mcap2.4% of flowCommon StockSEC:0001193125-26-201489:0
6,032 shares@ US$2.590.30% mcap25.7% of flowCommon StockSEC:0001193125-26-201474:0
6,515 shares@ US$2.590.33% mcap1.7% of flowCommon StockSEC:0001193125-26-201557:0
5,622 shares@ US$2.892.4% of flowCommon StockSEC:0001193125-26-014116:0
5,406 shares@ US$2.8925.9% of flowCommon StockSEC:0001193125-26-014117:0
5,839 shares@ US$2.891.7% of flowCommon StockSEC:0001193125-26-014115:0
5,340 shares@ US$3.161.7% of flowCommon StockSEC:0001193125-25-301033:0
5,142 shares@ US$3.162.4% of flowCommon StockSEC:0001193125-25-301026:0
4,183 shares@ US$3.1622.1% of flowCommon StockSEC:0001193125-25-301025:0
10,775 shares0Common StockSEC:0000950170-25-110531:0
4,050 shares0Common StockSEC:0000950170-25-094387:0
3,400 shares0Common StockSEC:0000950170-25-094386:0
17,465 shares0Common StockSEC:0000950170-25-054429:0
25 of 70 declarations
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a biopharmaceutical company focused on developing cell therapies for cancer treatment. It utilizes innovative technology to create personalized treatments for patients.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
